Table 3.
Characteristics of clinical COVID‐19 and MERS studies
| COVID‐19 published (n = 242) | MERS published (n = 13) | ||
|---|---|---|---|
| Study population | Adults | 209 (86.4%) | 11 (84.6%) |
| Children | 16 (6.6%) | 0 (0.0%) | |
| Pregnant adults | 7 (2.9%) | 0 (0.0%) | |
| Healthcare workers | 10 (4.1%) | 2 (15.4%) | |
| Study design | Case report | 65 (26.9%) | 1 (7.7%) |
| Case series | 105 (43.4%) | 5 (38.5%) | |
| Observational | 64 (26.4%) | 5 (38.5%) | |
| Interventional | 5 (2.1%) | 2 (15.4%) | |
| Novel conjunctival secretion RT‐PCR test | – | ||
| Novel rapid IgM–IgG antibody test | – | ||
| Ribavirin, interferon‐alpha | – | ||
| lopinavir/ritonavir | – | ||
| Oxygenation‐assisted tracheal intubation | – | ||
| Lopinavir/ritonavir | – | ||
| Other | 3 (1.2%) | 0 (0.0%) | |
| Study focus | Definition of disease | 126 (52.1%) | 5 (38.5%) |
| Diagnosis/screening | 81 (33.5%) | 5 (38.5%) | |
| Prevention | 15 (6.2%) | 0 (0.0%) | |
| Treatment | 13 (5.4%) | 3 (23.1%) | |
| Resource use | 1 (0.4%) | 0 (0.0%) | |
| Other miscellaneous | 6 (2.5%) | 0 (0.0%) |
RT‐PCR, real‐time reverse transcription polymerase chain reaction.